Oxford Asset Management’s Genetic Technologies Ltd. GENE Stock Holding History

Oxford Asset Management’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,560	Closed	-$193K	–	918
2015 Q4	$193K	Buy	+3,560	New	+$180K	﹤0.01%	799

Other funds holding GENE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Oxford Asset Management's GENE Position: Q1 2016 in Review

Oxford Asset Management sold out of Genetic Technologies Ltd. (GENE) in Q1 2016, closing a stake of 3,560 shares — an estimated $193K sold.

Oxford Asset Management first reported a position in GENE in Q4 2015 and held it in 1 quarter. The position peaked at $193K in Q4 2015. 10 funds tracked by Wall St. Rank hold GENE as of Q1 2016.

Oxford Asset Management reported no remaining Genetic Technologies Ltd. position as of Q1 2016 after selling out during the quarter.
Oxford Asset Management sold 3,560 Genetic Technologies Ltd. shares in Q1 2016, an estimated $193K.
Oxford Asset Management first reported a position in Genetic Technologies Ltd. in Q4 2015 and held it in 1 quarter.
Oxford Asset Management's Genetic Technologies Ltd. position peaked at $193K in Q4 2015.
10 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q1 2016.

Based on Oxford Asset Management's 13F filing for Q1 2016, filed 9 May 2016.